Hochhaus, Andreas

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia

Acute Myeloid Leukemia ResearchHistiocytic Disorders and Treatments

Cited by 4,274

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,547

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 1,139

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 947

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology

Colorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas

Cited by 509

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 351

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Cortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 208

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 194

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Hochhaus, A., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y.-T., le Coutre, P., Takahashi, N., Kim, I., Etienne, G., et al. (2024) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 171

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., Apperley, J. F., Lomaia, E., Voloshin, S., Turkina, A., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 148

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 139

B-cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies

Xiao, G., Chan, L. N., Klemm, L., Braas, D., Chen, Z., Geng, H., Zhang, Q. C., Aghajanirefah, A., Cosgun, K. N., Sadras, T., et al. (2018) · Cell

Cancer, Hypoxia, and MetabolismRedox biology and oxidative stress

Cited by 129

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 120

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 96

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 91

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Radich, J. P., Hochhaus, A., Masszi, T., Hellmann, A., Stentoft, J., Casares, M. T. G., García-Gutiérrez, J. V., Conneally, E., le Coutre, P. D., Gattermann, N., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 91

Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α

Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R., & Neubauer, A. (2001) · Blood

Chronic Myeloid Leukemia TreatmentsProtein Tyrosine Phosphatases

Cited by 77

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Schönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., Fabisch, C., Brümmendorf, T. H., Burchert, A., le Coutre, P., et al. (2022) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 57

Dasatinib

Lindauer, M., & Hochhaus, A. (2010) · Recent Results in Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 57

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Human MAIT cells are rapidly activated by Aspergillus spp. in an APC‐dependent manner

Jahreis, S., Böttcher, S., Hartung, S., Rachow, T., Rummler, S., Dietl, A., Haas, H., Walther, G., Hochhaus, A., & von Lilienfeld‐Toal, M. (2018) · European Journal of Immunology

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 51

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 50